Gerresheimer stock slides after a 2026 outlook cut
Published on 08/17/2026 at 17:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gerresheimer stock (DE000A0LD6E6) is under pressure after a report on August 16, 2026 said management now expects 2026 revenue in the lower half of its EUR 2.3 billion to EUR 2.4 billion range. The shares last closed at EUR 27.44 on August 17, 2026, and the market value stood at EUR 938.11 million.
Guidance reset
The same report said the stock was 42 percent below its 52-week high of EUR 46.74, with a 50-day moving average of EUR 27.11. That leaves the latest close of EUR 27.44 only slightly above that technical marker, which keeps the tape tight after the outlook change.
On the operating side, the most recent full-year figure in the source set shows revenue of EUR 2.32 billion for fiscal 2025, while TTM net income was minus EUR 320.32 million and TTM EPS was minus EUR 9.27. The comparison is straightforward: the 2026 revenue guide now points to a range that starts just above the prior fiscal year level.
Most recent report
For the latest reported period, the source set shows fiscal 2025 revenue of EUR 2.320885 billion, up 16.6 percent year over year, and diluted EPS of minus EUR 9.27 after EUR 2.38 in fiscal 2024. Gross profit in the trailing 12 months reached EUR 425.25 million, with EBITDA at EUR 312.91 million.
That mix matters because the stock is now trading well below its August 2025 high even after a week that showed a 5.86 percent gain from EUR 25.92 to EUR 27.44. The market is still reacting to the gap between a growth story and a margin profile that has turned weak in the latest reported numbers.
Product angle
Gerresheimer's packaging and delivery systems for injectable drugs remain central to the business, especially prefillable syringes, vials, ampoules, inhalers, and insulin pen systems. Those products tie the company directly to pharmaceutical demand and customer order visibility.
More on Gerresheimer stock: the current setup now depends on whether the market begins to trust the new revenue range or keeps focusing on the downside versus the 52-week high.
Price level
Gerresheimer stock last closed at EUR 27.44 on August 17, 2026. The 52-week range was EUR 14.83 to EUR 46.72, and the stock traded at EUR 27.28 in the latest intraday snapshot.
Company details
Company: Gerresheimer AG
ISIN: DE000A0LD6E6
Ticker: GXI
Exchange: Xetra
Price (as of August 17, 2026): EUR 27.44
Market cap: EUR 938.11 million
Sector / Industry: Health Care / Pharmaceuticals and healthcare packaging
Index membership: SDAX
